In patients with previously treated mCRPC, the addition of 177Lu-PSMA-617 to standard of care resulted in improvements in health-related quality of life and time to worsening of pain and first symptomatic skeletal events, in addition to the previously reported OS and rPFS benefits.
Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care
Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022
Video discussion by Drs. Wassim Abida, Heather Cheng, and Maha Hussain on optimal use of PARP inhibitors in prostate cancer, from Clinical Care Options (CCO)
Clinical Care Options (CCO): Atish Choudhury, MD, PhD, provides insights into new and evolving treatment approaches in CSPC, including data from 2022 ASCO GU Cancers Symposium